| Excerpt | Reference |
|---|
| "Deep venous thrombosis is 1 of the most common postoperative complications resulting in significant mortality and morbidity in patients undergoing total hip and total knee arthroplasty." | ( Bailey, M; Del Schutte, H; McEvoy, MD; Taylor, D, 2000) |
| "Deep vein thrombosis is a common condition which may occur spontaneously or after surgery." | ( Chong, BH, 2001) |
| "Deep venous thrombosis is the most common complication in patients having elective total knee replacement." | ( Bottner, F; Sculco, TP, 2001) |
| "Catheter-related venous thrombosis is one of the most frequent complications of central venous catheters (CVCs)." | ( Bach, A; Egerer, G; Goldschmidt, H; Harter, C; Ho, AD; Salwender, HJ, 2002) |
| "Treatment of deep vein thrombosis is founded on the association of low molecular weight heparin and oral anticoagulant for three or six months." | ( Fiessinger, JN, 2001) |
| "Deep vein thrombosis is a condition associated with common complications, both in the acute period and in the long-term." | ( Armengol, JG; Fernández-Cruz, A; Jiménez Rodríguez-Madridejos, R; Martín-Carbonero, L; Pedrajas, JM; Salgado, X, 2002) |
| "Lower extremity deep vein thrombosis is often isolated to the sinusoidal veins draining the gastrocnemius and soleus muscles." | ( Kahn, SR; Macdonald, PS; Miller, N; Obrand, D, 2003) |
| "The risk of venous thrombosis is also higher for preparations containing desogestrel or gestodene (third-generation progestogens) than for those containing levonorgestrel (second-generation progestogens)." | ( Helmerhorst, FM; Rosendaal, FR; Tanis, BC; Van Hylckama Vlieg, A, 2003) |
| "Treatment of deep venous thrombosis is founded on the association of low molecular heparins and oral anticoagulants for 3-6 months." | ( Bura-Riviere, A; Fiessinger, JN, 2003) |
| "Catheter-related deep venous thrombosis is a complication that can occur in patients receiving chemotherapy." | ( Albertsson, M; Tham, J, 2004) |
| "Deep vein thrombosis is important social and health care problem for its high incidence, pulmonary embolism-related mortality, and long-term sequelae which may be disabling (post-thrombotic syndrome and ulceration)." | ( Ignjatović, N; Karanikolić, A; Mihajlović, D; Milić, D; Pejić, M; Stojiljković, D; Visnjić, A; Zivić, S; Zlatić, A, 2003) |
| "Deep vein thrombosis is the most popular disease among the venous obstruction morbidity." | ( Endo, M; Kasashima, F; Kawakami, K; Matsumoto, Y; Sasaki, H; Ueyama, T, 2005) |
| "Deep vein thrombosis is a potential complication in patients admitted to cardiac rehabilitation programs after acute coronary syndromes, episodes of acute congestive heart failure, and cardiac revascularization." | ( Ageno, W; Ambrosetti, M; Pedretti, RF; Salerno, M; Tramarin, R, 2005) |
| "The risk of venous thrombosis is the highest in the first year of therapy, durich which as much as a greater than 6-fold increase was found." | ( Wu, O, 2005) |
| "Cerebral venous thrombosis is a relatively uncommon condition afflicting mostly young adults." | ( AlKawi, A; Ilyas, A; Ilyas, MS; Khatri, IA, 2006) |
| "The incidence of deep vein thrombosis is lower than previously reported in the literature." | ( Falco, P; Lacy, M; Menon, SP; Palumbo, A; Rajkumar, SV, 2008) |
| "This dual effect on venous thrombosis is a consequence of two actions, one that inhibits thrombin and factor Xa and one that induces factor XII activation." | ( Melo, FR; Mourão, PA, 2008) |
| "Deep vein thrombosis is a condition, which has several acquired as well as genetic causes." | ( Akhter, MS; Bajaj, J; Biswas, A; Meena, A; Ranjan, R; Saxena, R; Sharma, V; Yadav, BK, 2008) |
| "Cerebral venous thrombosis is an uncommon and diverse entity accounting for less than 1% of strokes." | ( Carroll, A; Soong, MM, 2010) |
| "Residual venous thrombosis is an important risk factor for recurrent thromboembolism and PTS." | ( Castrodeza, J; González-Fajardo, JA; Martin-Pedrosa, M; Tamames, S; Vaquero-Puerta, C, 2008) |
| "The incidence of deep venous thrombosis is 0." | ( Baroncini, LA; de Oliveira, A; França, GJ; Stalke, PS; Vidal, EA, 2008) |
| "Cerebral venous thrombosis is an uncommon disease characterized by expansive cerebral edema, venous infarction and massive intracerebral hemorrhage." | ( Abe, T; Kato, N; Mori, R; Morita, M; Morooka, S; Noda, Y; Seki, K; Tanaka, T, 2009) |
| "Deep Venous Thrombosis is a common disease with fatal and serious long term burdensome complications." | ( Adekoya-Cole, TO; Enweluzo, GO; Giwa, SO; Obalum, DC; Ogo, CN, 2009) |
| "Deep venous thrombosis is common in the elderly." | ( Billett, HH; Jacobs, LG, 2009) |
| "The risk of venous thrombosis is unclear in the PCOS population, and further studies are urgently required to address whether first-line treatment for PCOS with oral contraceptive pills is advisable." | ( Dokras, A; Mak, W, 2009) |
| "A third site of rare venous thrombosis is the deep system of the upper extremities that, as for the lower extremity, can be complicated by pulmonary embolism and post-thrombotic syndrome." | ( De Stefano, V; Martinelli, I, 2010) |
| "Idiopathic venous thrombosis is associated with impaired flow- and GTN-mediated vasodilatory response of the brachial artery." | ( Jezovnik, MK; Poredos, P; Stalc, M, 2010) |
| "Cerebral venous thrombosis is a rare entity in pregnancy and the postpartum period, with an incidence of 1:10,000 to 1:25,000." | ( McCaulley, JA; Pates, JA, 2011) |
| "Deep venous thrombosis is mainly diagnosed by ultrasound today." | ( Aschwanden, M; Bilecen, D; Hügli, R; Jacobi, B; Partovi, S; Rasmus, M; Rengier, F; Staub, D; Zipp, L, 2011) |
| "Cerebral venous thrombosis is an uncommon condition with difficulties in diagnosis and treatment." | ( Cheng, PW; Hon, SF; Li, HL, 2012) |
| "Cerebral venous thrombosis is a rare condition with various clinical presentations which may delay diagnosis." | ( Basic-Jukic, N; Gledovic, B; Radunovic, D; Ratkovic, M, 2014) |
| "Deep venous thrombosis is a major health problem." | ( Andia, ME; Botnar, RM; Grover, SP; Jenkins, J; Modarai, B; Patel, AS; Phinikaridou, A; Saha, P; Schaeffter, T; Smith, A; Wiethoff, AJ, 2014) |
| "Iliofemoral deep vein thrombosis is a medical emergency associated with pulmonary embolism, severe postthrombotic morbidity and increased rates of recurrence." | ( Eluehike, S; Isabu, P; Kesieme, EB; Okokhere, P, 2014) |
| "Deep vein thrombosis is a common complication of immobilising the lower limb after surgery." | ( Ackermann, PW; Domeij-Arverud, E; Edman, G; Labruto, F; Latifi, A; Nilsson, G, 2015) |
| "Deep venous thrombosis is a common vascular problem with long-term complications including post-thrombotic syndrome." | ( Chabasse, C; McGilvray, KC; Mukhopadhyay, S; Nguyen, KP; Puttlitz, CM; Sarkar, R, 2015) |
| "Acute venous thrombosis is prevalent and potentially fatal." | ( Cui, C; Fan, Q; Hu, X; Jian, C; Ma, H; Qi, B; Shou, K; Wu, J; Yang, Z; Yu, A; Zhao, Y, 2017) |
| "Deep venous thrombosis is one of the common complications after major surgery in the Department of Orthopedics." | ( Nie, L; Xu, W; Yang, Z; Zhang, T, 2018) |
| "Deep vein thrombosis is a multifactorial disease with many acquired and genetic risk factors." | ( Ahluwalia, J; Das, R; Kumar, N; Rastogi, P; Senee, H; Suri, V; Varma, N, 2019) |
| "Deep venous thrombosis is a very common complication of orthopedic patients on bed rest." | ( Meng, X; Wang, B; Wang, Y; Zheng, G, 2018) |
| "As such, venous thrombosis is often a feature, and occasionally a presenting sign, of systemic disease." | ( Greenblatt, HK; Nguyen, BK, 2019) |
| "Cerebral venous thrombosis is rare and an uncommon cause of stroke and has diverse etiologies and varied clinical presentations." | ( Fujisawa, H; Shimizu, Y; Tsuchiya, K, 2019) |
| "Although venous thrombosis is a leading cause of flap failure, the majority of lower extremity free flap planning is centered on arterial system evaluation." | ( Akbari, C; Attinger, CE; Black, CK; Evans, KK; Hashmi, A; Janhofer, DE; Kim, PJ; Lakhiani, C; Naz, I; Tefera, EA, 2020) |
| "Deep vein thrombosis is a major source of morbidity and mortality worldwide." | ( Ahmed, O; Bader, KB; Bhargava, A; Hendley, SA; Holland, CK; Paul, JD; Wool, GD, 2022) |
| "Spontaneous venous thrombosis is often the first clinical sign of cancer, and it is linked to a worsened survival rate." | ( Crescence, L; Dubois, C; Langiu, M; Mege, D; Palacios-Acedo, AL; Panicot-Dubois, L, 2022) |
| "However, upper limb deep vein thrombosis is poorly studied with scant data on the use of direct oral anticoagulants in noncatheter-related deep vein thrombosis." | ( Fioretti, AM; Giotta, F; Leopizzi, T; Lorusso, V; Luzzi, G; Oliva, S; Puzzovivo, A, 2022) |
| Excerpt | Reference |
|---|
| "The long-term risk for recurrent deep venous thrombosis (DVT) and the incidence of post-thrombotic syndrome (PTS) after long-term anticoagulation (LTA) therapy have been widely debated." | ( AbuRahma, AF; Robinson, PA; Stickler, DL, 1998) |
| "To assess whether uncomplicated deep vein thrombosis could be treated in an out-patient setting without increasing the frequency of complications, and to determine the proportion of patients with deep vein thrombosis, traditionally treated as in-patients at the Departments of Medicine, who are eligible for such treatment." | ( Berntorp, E; Bornhov, S; Lagerstedt, C; Lethagen, S; Mattiasson, I; Persson, J; Timberg, I; Torstensson, I, 1998) |
| "Uncomplicated acute deep vein thrombosis could be safely treated on an out-patients basis." | ( Berntorp, E; Bornhov, S; Lagerstedt, C; Lethagen, S; Mattiasson, I; Persson, J; Timberg, I; Torstensson, I, 1998) |
| "Prevention of recurrent venous thrombosis and pulmonary embolism is the main reason for accurate diagnosis and adequate treatment." | ( Büller, HR; Lensing, AW; Prandoni, P; Prins, MH, 1999) |
| "Guidelines for prophylaxis of deep vein thrombosis (DVT) after hip replacement surgery suggest the use of twice-daily low-molecular-weight heparin as one treatment option." | ( Wade, WE, 1999) |
| "Treatment options for deep vein thrombosis (DVT) have expanded in recent years and now include systemic anticoagulation, thrombolytic therapy, and surgery." | ( Burroughs, KE, 1999) |
| "We report on a breastfeeding woman with deep venous thrombosis treated with hirudin because of heparin-induced thrombocytopenia, in whom hirudin was not detectable in human breastmilk." | ( Bauersachs, R; Lindhoff-Last, E; Nowak, G; Thalhammer, C; Willeke, A, 2000) |
| "Based on the current understanding that venous thrombosis starts perioperatively, administration of just-in-time low-molecular-weight heparin immediately before or in close proximity after hip arthroplasty may be more effective than usual clinical practice." | ( Baylis, B; Bergqvist, D; Brant, R; Dear, R; Fellenius, C; Francis, C; Holmqvist, A; Hull, RD; Mah, A; Mant, M; Pineo, GF; Soderberg, K, 2000) |
| "Therapy to prevent deep venous thrombosis (DVT) and pulmonary embolism remains essential for inpatients, despite short periods of bedrest and hospitalization." | ( Shively, BK, 2001) |
| "The choice of therapy for deep vein thrombosis (DVT) of the lower extremity during pregnancy has been widely debated." | ( Aburahma, AF; Mullins, DA, 2001) |
| "Androgen was reported to cause cerebral venous thrombosis (CVT) during replacement therapy for aplastic anemia." | ( Chu, K; Kang, DW; Kim, DE; Roh, JK, 2001) |
| "Outpatient treatment of deep venous thrombosis (DVT) with low molecular weight heparin (LMWH) seems as safe and effective as inpatient treatment with unfractionated heparin (UFH)." | ( Ferrer, R; Grau, E; Medrano, J; Pastor, E; Real, E; Selfa, S; Tenias, JM, 2001) |
| "The accurate diagnosis of deep vein thrombosis (DVT) is essential to prevent its complications and to initiate appropriate treatment." | ( Huang, YF; Ilkhanizadeh, R; Joyce Chen, YW; Kalani, J; Magzadeh, P; Ratani, RS; Yang, DC, 2001) |
| "Therapy for deep vein thrombosis (DVT) resolution in those patients in whom a complication or contraindication to anticoagulation occurs is limited." | ( Fowlkes, JB; Hawley, A; Henke, PK; Kadell, AM; Linn, MJ; Sarkar, M; Strieter, RM; Varma, MR; Wakefield, TW, 2001) |
| "In patients with idiopathic deep venous thrombosis, continuing anticoagulant therapy beyond three months is associated with a reduced incidence of recurrent thrombosis during the period of therapy." | ( Ageno, W; Agnelli, G; Bagatella, P; Bazzan, M; Bertoldi, A; Guazzaloca, G; Iorio, A; Moia, M; Prandoni, P; Santamaria, MG; Scannapieco, G; Tomasi, C, 2001) |
| "In patients with idiopathic deep venous thrombosis, the clinical benefit associated with extending the duration of anticoagulant therapy to one year is not maintained after the therapy is discontinued." | ( Ageno, W; Agnelli, G; Bagatella, P; Bazzan, M; Bertoldi, A; Guazzaloca, G; Iorio, A; Moia, M; Prandoni, P; Santamaria, MG; Scannapieco, G; Tomasi, C, 2001) |
| "(1) In the prevention of deep venous thrombosis after hip surgery, the recommended treatment period with dalteparin has been extended from seven days to 35 days." | ( , 2000) |
| "This article focuses on deep vein thrombosis (DVT) and anticoagulant therapy." | ( Ortiz, EJ; Sullano, MA, 2001) |
| "Standard treatment of deep venous thrombosis (DVT) previously required hospitalization so patients could receive continuous intravenous infusion of unfractionated heparin." | ( , 1999) |
| "Treatment and prevention of deep vein thrombosis (DVT) raise a number of important economic issues." | ( de Lissovoy, G, 2001) |
| "Home treatment of deep vein thrombosis (DVT) has been shown to be safe and effective." | ( Beyer, J; Schellong, SM; Schmidt, B; Schröder, HE; Schwarz, T, 2001) |
| "The low overall incidence of central venous thrombosis might be attributed to the routine application of low-dose heparin in our patients during chemotherapeutic treatment." | ( Bach, A; Egerer, G; Goldschmidt, H; Harter, C; Ho, AD; Salwender, HJ, 2002) |
| "Subjects with an ultrasound-confirmed deep venous thrombosis had prothrombin fragment 1+2 (F 1+2), tissue plasminogen activator (t-PA) activity, plasminogen activator inhibitor (PAI-1) activity, and t-PA antigen levels determined before anticoagulation therapy." | ( Bergelin, RO; Chandler, WL; Meissner, MH; Strandness, DE; Zierler, BK, 2002) |
| "Outpatient treatment of acute proximal deep vein thrombosis with enoxaparin has also been shown to be cost effective compared with inpatient treatment using UFH." | ( Bergqvist, D, 2002) |
| "Treatment of deep vein thrombosis is founded on the association of low molecular weight heparin and oral anticoagulant for three or six months." | ( Fiessinger, JN, 2001) |
| "To assess the outcome of deep vein thrombosis in patients with malignancy after 6 months of oral anticoagulant therapy, and to compare it with international normalized ratio (INR)." | ( Ostojić, R; Svircić, T; Vucić, N, 2002) |
| "We report a patient who developed deep vein thrombosis of the calf and thrombophlebitis after treatment with intracorporeal alprostadil (Viridal)." | ( Aihaku, EK; Barthelmes, L; Chezhian, C, 2002) |
| "Moreover, in the thrombin-induced rat venous thrombosis model, the dose-dependent thrombolysis was also observed by oral administration of JTV-926." | ( Fukao, H; Hayashi, M; Horibuchi, K; Matsuno, H; Matsuo, O; Okada, K; Uematsu, T; Ueshima, S, 2002) |
| "Patients with acute deep vein thrombosis (DVT) were treated with a body-weight independent dosage of 2 x 8000 aXa IU low-molecular-weight heparin (LMWH) Certoparin." | ( Harenberg, J, 2002) |
| "Outpatient treatment of deep venous thrombosis has gained widespread acceptance and is facilitated by the use of subcutaneous low molecular weight heparins (LMWH)." | ( Begelman, SM; Deitcher, SR, 2002) |
| "In this report, we describe two new venous thrombosis cases occurring during a treatment with thalidomide." | ( Gachon, J; Grob, JJ; Richard, MA, 2002) |
| "LMWHs are recommended for treating deep vein thrombosis (DVT)." | ( Bussey, H, 2002) |
| "Combination treatment in acute deep venous thrombosis essentially consists of a highly dosed locoregional thrombolysis of the valve-carrying crurofemoral axis and a mechanical thrombectomy of the valveless pelvic axis by Fogarty catheter." | ( Blättler, W; Gloor, B; Largiadèr, J, 2002) |
| "in the treatment of deep venous thrombosis." | ( Reverter, JC, 2002) |
| "Patients with deep venous thrombosis (DVT) treated out of hospital usually start warfarin with the recommended 5 mg loading dose and have their International Normalized Ratio (INR) test performed every 2-3 days." | ( Ageno, W; Dentali, F; Marchesi, C; Mera, V; Squizzato, A; Steidl, L; Ultori, C; Venco, A, 2003) |
| "The treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) in pregnant patients is challenging for several reasons." | ( Bates, SM, 2002) |
| "Therefore outpatient treatment of deep venous thrombosis is possible in most patients." | ( Rüfer, A; Wuillemin, WA, 2003) |
| "Treatment of deep venous thrombosis is founded on the association of low molecular heparins and oral anticoagulants for 3-6 months." | ( Bura-Riviere, A; Fiessinger, JN, 2003) |
| "The incidence of venous thrombosis associated with estrogen treatment in male-to-female (M-->F) transsexuals is considerably higher with administration of oral ethinyl estradiol (EE) than with transdermal (td) 17-beta-estradiol (E(2))." | ( Gooren, LJ; Magdeleyns, EJ; Rosing, J; Tans, G; Thomassen, MC; Toorians, AW; Zweegman, S, 2003) |
| "A decision is made to treat the calf deep venous thrombosis (DVT) with anticoagulation." | ( Caprini, JA; Deitcher, SR, 2003) |
| "Prophylactic treatment against deep vein thrombosis has become a routine part of surgical treatment." | ( Haas, S, 2004) |
| "Catheter-related deep venous thrombosis is a complication that can occur in patients receiving chemotherapy." | ( Albertsson, M; Tham, J, 2004) |
| "Early detection of asymptomatic deep vein thrombosis by venous sonography may identify patients who may benefit from anticoagulant therapy and thus may prevent morbidity and mortality associated with deep vein thrombosis." | ( Bar-Sela, G; Bernstein, R; Brenner, B; Gaitini, D; Haim, N; Sarig, G, 2004) |
| "The early detection of deep venous thrombosis (DVT) and treatment with systemic anticoagulation to prevent pulmonary embolism (PE) are essential in the management of patients undergoing total joint arthroplasty (TJA)." | ( Endean, ED; Hartford, JM; Kwolek, CJ; Matthews, MR; Mentzer, RM; Minion, DJ; Quick, RC; Schwarcz, TH, 2004) |
| "Clinical relevance Improved therapy for deep venous thrombosis (DVT) will ideally increase the rate of thrombus dissolution and eliminate the bleeding risks of anticoagulation." | ( Deatrick, KB; Dewyer, NA; Henke, PK; Kunkel, SL; Moaveni, DM; Upchurch, GR; Varga, AJ; Varma, MR; Wakefield, TW, 2004) |
| "Despite successful treatment, deep vein thrombosis may not fully resolve in some patients." | ( Kearon, C; Linkins, LA; Pasquale, P; Paterson, S, 2004) |
| "To report final data on incidence of venous thrombosis in the Women's Health Initiative Estrogen Plus Progestin clinical trial and the association of hormone therapy with venous thrombosis in the setting of other thrombosis risk factors." | ( Cushman, M; Kuller, LH; Prentice, R; Psaty, BM; Rodabough, RJ; Rosendaal, FR; Sidney, S; Stafford, RS, 2004) |
| "To report cerebral venous thrombosis as a complication of intravenous corticosteroid treatment in a patient with multiple sclerosis." | ( Balaban, H; Eldem, B; Gedik, S; Kadayifçilar, S; Kansu, T, 2004) |
| "Current antithrombotic therapy of deep vein thrombosis (DVT) consists of an initial course of heparin, followed by the secondary prevention with oral anticoagulation (OAC)." | ( Bauersachs, RM, 2004) |
| "A case of deep vein thrombosis treated with the standard warfarin dose is investigated for intensity of anticoagulation and CYP2C9 genotype; the case illustrates the relationship between CYP2C9 variant and overanticoagulation with subsequent bleeding complication." | ( Adcock, DM; Crisan, D; Kiechle, FL; Koftan, C, 2004) |
| "The primary end points of the study were deep vein thrombosis (DVT), confirmed by venography of the CVC limb performed 6 weeks after randomization, or clinically overt pulmonary embolism, confirmed by objective testing during the study drug administration." | ( Ageno, W; Agnelli, G; Bazzan, M; Bertoglio, S; Di Somma, FC; Imberti, D; Mosca, S; Naglieri, E; Paoletti, F; Parise, P; Quintavalla, R; Santoro, A; Sorarù, M; Verso, M, 2005) |
| "In outpatients with suspected deep venous thrombosis who initially had normal results on ultrasonography of the proximal veins, a strategy based on D-dimer testing followed by no further testing if the result was negative and venography if the result was positive had acceptable safety and did not differ from the safety of a strategy based on withholding anticoagulant therapy and routinely repeating ultrasonography after 1 week." | ( Bates, SM; Brill-Edwards, P; Crowther, MA; Douketis, J; Finch, T; Gent, M; Ginsberg, JS; Kearon, C; Lee, A; Turpie, AG, 2005) |
| "Outpatient treatment of deep vein thrombosis (DVT) has become a common practice in uncomplicated patients." | ( Abbadessa, V; Anastasio, R; Arcara, C; Bajardi, G; Fulfaro, F; Gebbia, N; Grimaudo, S; Lo Coco, L; Malato, A; Siragusa, S; Valerio, MR, 2005) |
| "Therapy against deep venous thrombosis must be focused on its prevention in the future." | ( Bitsori, M; Charissis, G; Papakonstantinou, O; Sakellaris, G; Tilemis, S; Tsetis, D, 2005) |
| "Patients with deep venous thrombosis or pulmonary embolism received warfarin therapy; those with negative venograms received no further anticoagulation." | ( Donaldson, CT; Evarts, CM; Farber, DC; Lehman, EB; Pellegrini, VD, 2005) |
| "Twenty-one of the 131 patients developed venous thrombosis during thalidomide treatment." | ( Baumann, MA; Ikhlaque, N; Kathula, S; Seshadri, V, 2006) |
| "After 48 h, the rate of venous thrombosis, as evaluated microscopically, was significantly decreased in hemodiluted animals (1/8) as compared with controls (10/10); in rats treated with dextran-40 (7/10) and enoxaparin (5/10) the rate of venous thrombosis was significantly higher as compared with rats of the group hemodiluted." | ( Campos, AD; Farina, JA; Piccinato, CE; Rossi, MA, 2006) |
| "It is critical to treat deep venous thrombosis at an early stage to avoid development of further complications, such as pulmonary embolism or recurrent deep venous thrombosis." | ( Barry, P; Bass, EB; Green, L; Hornbake, ER; Ireland, B; Owens, DK; Qaseem, A; Rodnick, JE; Segal, JB; Snow, V; Tobolic, T; Weiss, KB, 2007) |
| "The portal venous thrombosis in this case disappeared 2 weeks commencing after administration of danaparoid sodium." | ( Honda, M; Shudo, R; Sugawara, K; Yazaki, Y, 2007) |
| "We present a case of deep venous thrombosis (DVT) during pegylated interferon (peg-IFN)-alpha2b plus ribavirin treatment of chronic hepatitis C (CHC)." | ( Adachi, K; Iino, S; Ishii, T; Itoh, F; Katakura, Y; Matsumoto, N; Matsunaga, K; Okuse, C; Suzuki, M; Yotsuyanagi, H, 2006) |
| "Death from deep vein thrombosis or pulmonary embolism; failure to resolve, extension, recurrence of during treatment; recurrence after treatment; and major haemorrhage during treatment." | ( Bentley, DP; Campbell, IA; Prescott, RJ; Routledge, PA; Shetty, HG; Williamson, IJ, 2007) |
| "During treatment deep vein thrombosis or pulmonary embolism failed to resolve, extended, or recurred in six patients in the three month group without fatal consequences, compared with 10 in the six month group." | ( Bentley, DP; Campbell, IA; Prescott, RJ; Routledge, PA; Shetty, HG; Williamson, IJ, 2007) |
| "The article contains data on venous thrombosis (VT) recurrence rate in patients with the first episode of thrombus formation after the completion of one-year therapy with warfarin." | ( Kozlova, TV, 2006) |
| "Such occurrence of catheter-related deep venous thrombosis led to the assumption that disintegration of intravenous tubing resulted in intravenous administration of debris." | ( Braet, F; Danschutter, D; Hachimi-Idrissi, S; Huyghens, L; Moloney-Harmon, P; Van Bruwaene, B; Van Gyseghem, E, 2007) |
| "In the venous thrombosis (treatment) model, intravenous (1." | ( Biemond, BJ; Buetehorn, U; Büller, HR; Friederich, PW; Levi, M; Perzborn, E, 2007) |
| "The long-term complications of deep vein thrombosis (DVT), assessment of risk for venous thromboembolism (VTE) in medical and surgical patients, recommendations in evidence-based guidelines for VTE prophylaxis in surgical and medical patients and the treatment of VTE, and a new alternative for VTE prophylaxis and treatment are discussed." | ( Nutescu, EA, 2007) |
| "A 79-year-old man with a history of deep vein thrombosis and pulmonary embolism received anticoagulation therapy with warfarin 5 mg daily for 8 months." | ( Alexandropoulos, H; Epplen, K; Foruhari, F; Kim, KY, 2007) |
| "BD patients with venous thrombosis were divided into three groups: one group (N = 16) received immunosuppressive therapy alone, another group (N = 17) received immunosuppressant and anticoagulation combination therapy, and the third group (N = 4) received anticoagulation therapy only." | ( Ahn, JK; Cha, HS; Jeon, CH; Koh, EM; Lee, YS, 2008) |
| "A 39-year-old man with a history of deep vein thrombosis and septic arthritis of the left knee was treated with warfarin and cefazolin." | ( Epplen, K; Foruhari, F; Frey, RJ; Kim, KY, 2007) |
| "Recurrent deep venous thrombosis despite well conducted anticoagulant treatment is an uncommon, but possible, event." | ( Ageno, W; Büller, HR; Gerdes, VE; Romualdi, E; Squizzato, A; Vitale, J, 2007) |
| "Although the risk of deep vein thrombosis on thalidomide therapy has been well documented, only a few cases have been noted documenting the risk of stroke during thalidomide therapy." | ( Hashimoto, Y; Hirano, T; Ito, Y; Mori, A; Uchino, M; Yonemura, K, 2007) |
| "Accurate diagnosis of acute recurrent deep vein thrombosis (DVT) is relevant to avoid improper diagnosis and unnecessary life-long anticoagulant treatment." | ( De Bats, MJ; De Roos, A; Huisman, MV; Kok, S; Tan, M; Van Gils, AP; Van Rooden, CJ; Westerbeek, RE, 2008) |
| "A 71-year-old man with deep venous thrombosis treated with fenprocoumon presented after a trauma with a haematoma due to an INR > 8." | ( van Thiel, SW; Vlasveld, LT, 2008) |
| "It has recently been associated with deep venous thrombosis (DVT) when used in treatment of refractory multiple myeloma along with combination chemotherapy." | ( Pise, GA; Thappa, DM; Vetrichevvel, TP, 2008) |
| "We have studied the risk of venous thrombosis with use of statins, other lipid-lowering medication, and antiplatelet therapy." | ( Doggen, CJ; Mantel-Teeuwisse, AK; Ramcharan, AS; Rosendaal, FR; Snoep, JD; Van Stralen, KJ, 2009) |
| "Antiplatelet therapy also reduced venous thrombosis risk (OR 0." | ( Doggen, CJ; Mantel-Teeuwisse, AK; Ramcharan, AS; Rosendaal, FR; Snoep, JD; Van Stralen, KJ, 2009) |
| "The optimal treatment of isolated distal deep vein thrombosis (ID-DVT) is still controversial." | ( Antignani, PL; Camporese, G; Lessiani, G; Palareti, G; Parisi, R; Verlato, F; Visonà, A, 2009) |
| "Medical activities for prevention of deep vein thrombosis (DVT), early detection of DVT, and early treatment of DVT were performed immediately after the earthquake on the basis of a previous report regarding earthquake disasters." | ( Asakura, H; Fujita, S; Kimura, K; Morishita, E; Ohba, N; Ohtake, H; Terakami, T; Wada, T; Watanabe, G; Yoshida, T, 2009) |
| "first venous thrombosis) should be treated with warfarin to an INR 2." | ( Khamashta, MA; Tuthill, JI, 2009) |
| "Recently, increased incidence of venous thrombosis following thalidomide use has been reported in the treatment of diseases with disease-related thrombotic risks, such as malignancy and lupus with antiphospholipid antibody syndrome, as well as concomitant therapy with chemotherapy and/or systemic corticosteroids." | ( Boone, SL; Fabi, SG; Hill, C; West, DP; Witherspoon, JN, 2009) |
| "Leg venography confirmed deep vein thrombosis, and thrombolytic therapy was performed to eliminate symptoms." | ( Akira, S; Ichikawa, M; Iwasaki, N; Kuwabara, Y; Mine, K; Tajima, H; Takeshita, T, 2009) |
| "The risk of venous thrombosis is unclear in the PCOS population, and further studies are urgently required to address whether first-line treatment for PCOS with oral contraceptive pills is advisable." | ( Dokras, A; Mak, W, 2009) |
| "In a rat deep venous thrombosis model used to assess antithrombotic efficacy, oral administration of 8 at 30 and 50 mg/kg reduced thrombus weight by 87 and 94%, respectively." | ( Andrade-Gordon, P; Ballentine, SK; Bone, RF; Brown, K; Crysler, CS; Damiano, BP; End, D; Giardino, EC; Lu, T; Markotan, T; Maryanoff, BE; Player, MR; Shukla, U; Spurlino, J; Tomczuk, BE, 2010) |
| "The cancer patients with deep venous thrombosis (DVT) and without pulmonary embolism (PE) were randomised to standard treatment or a once-weekly subcutaneous injection of idraparinux (2." | ( Büller, HR; Cohen, AT; Davidson, BL; Decousus, H; Gallus, AS; Gent, M; Piovella, F; Prins, MH; Raskob, GE; van Doormaal, FF, 2010) |
| "The symptoms were attributed to venous thrombosis and resolved with systemic anticoagulation after five days of treatment." | ( Gobin, YP; Knopman, J; Patsalides, A; Riina, HA; Zink, W, 2010) |
| "A 73-year-old woman with a history of deep venous thrombosis of the lower limbs was treated with sunitinib for renal cancer with hepatic and pulmonary secondaries." | ( Barbaud, A; Cuny, JF; Granel-Brocard, F; Guyot-Caquelin, P; Marchal, A; Schmutz, JL; Spaeth, D; Trechot, P, 2010) |
| "We report two cases of venous thrombosis confirmed during the bevacizumab combination chemotherapy for colorectal cancer." | ( Hosokawa, T; Iwao, Y; Koshiishi, H; Koshinaga, T; Matsuyama, T; Nishida, K; Okamura, T; Sakamoto, K; Tokita, H, 2010) |
| "To compare venous thrombosis rates among animals treated with aspirin, clopidogrel bisulfate, and ketorolac tromethamine using an anastomotic "tuck" model." | ( Harsha, WJ; Hayden, RE; Kau, RL; Kim, N, 2011) |
| "We determined the incidence of deep vein thrombosis and pulmonary embolism in patients having surgery for displaced proximal humerus fractures treated with our thromboprophylactic regimen." | ( Abboud, JA; Bassora, R; Warrender, WJ; Widmer, BJ, 2011) |
| "A clear diagnosis of deep venous thrombosis (DVT) is still challenging: many patients with unclear compression/duplex-sonography undergo a trial of anticoagulative treatment with the immanent risk of systemic hemorrhagic complications." | ( Gruber, H; Loizides, A; Ostermann, S; Peer, S; Plaikner, M; Spiss, V, 2011) |
| "Mouse models of venous thrombosis contribute to our understanding of the initiation, propagation, and resolution of venous thrombus, as well as allow for the evaluation of new pharmaceutical approaches to prophylaxis and treatment of deep vein thrombosis." | ( Diaz, JA; Henke, PK; Mackman, N; Myers, DD; Obi, AT; Wakefield, TW; Wrobleski, SK, 2012) |
| "Cerebral venous thrombosis is an uncommon condition with difficulties in diagnosis and treatment." | ( Cheng, PW; Hon, SF; Li, HL, 2012) |
| "The authors treated patients with deep vein thrombosis according to latest recommendations using D-dimer measurements and duplex ultrasound exams." | ( Bernát, SI; Rókusz, L, 2012) |
| "Its use has been associated with deep vein thrombosis in patients with blood disorders, however, particularly when used in combination with corticosteroids or chemotherapy." | ( Burgués-Calderón, M; de la Hera, I; Fuertes, L; Hebe Petiti-Martin, G; Rivera-Díaz, R; Vanaclocha, F; Villar-Buill, M, 2013) |
| "Understanding the mechanisms of venous thrombosis may lead to the development of new treatments." | ( Mackman, N, 2012) |
| "The hazard ratio for deep vein thrombosis (2 in treated group v 1 in control group) was 2." | ( Eiken, P; Jensen, JE; Køber, L; Mosekilde, L; Rejnmark, L; Schierbeck, LL; Stilgren, L; Tofteng, CL, 2012) |
| "Geniposide and genipin were studied on venous thrombosis by oral administration." | ( Liu, H; Wei, SF; Yang, M; Zhang, HY, 2013) |
| "A patient with a history of deep vein thrombosis presented with painful bruising and blistering on his left leg 7-10 days after warfarin treatment." | ( Bedlow, A; Biscoe, AL, 2013) |
| "In patients with deep venous thrombosis or pulmonary embolism, initial treatment with low-molecular-weight heparin (LMWH) is primarily aimed at preventing thrombus extension." | ( , 2013) |
| "The risk of venous thrombosis (VT) associated with oral hormone therapy (HT) may differ by type of estrogen compound." | ( Blondon, M; Harrington, LB; Heckbert, SR; McKnight, B; Psaty, BM; Rice, KM; Rosendaal, FR; Smith, NL; van Hylckama Vlieg, A; Wiggins, KL, 2014) |
| "Quality of treatment for acute venous thrombosis is determined by adequacy of conservative treatment and optimization of the operative procedure." | ( Durandin, PIu; Kletskin, AÉ; Kudykin, MN; Mukhin, AS, 2014) |
| "At two weeks, the incidence of deep vein thrombosis was 21% in the treated group and 37% in the control group (p = 0." | ( Ackermann, PW; Domeij-Arverud, E; Edman, G; Labruto, F; Latifi, A; Nilsson, G, 2015) |
| "Venous thromboembolism includes deep vein thrombosis and pulmonary embolism and is a serious medical condition that requires anticoagulation as part of treatment." | ( Law, EH; Leung, TS, 2015) |
| "Prevention of deep venous thrombosis (DVT) and associated pulmonary embolism following major orthopedic surgeries is challenging, and there is an increased interest in developing new treatment strategies." | ( Altıntaş, F; Önal, A; Özler, T; Uluçay, Ç, 2015) |
| "Outcomes were VTE events (defined as deep vein thrombosis [DVT], pulmonary embolism [PE], limb ischemia, transient ischemic attack, cerebrovascular accident, non-ST-segment elevation myocardial infarction, ST-segment elevation myocardial infarction, and unexplained sudden death) occurring within 30 days of 3F-PCC administration." | ( Felton, D; Foley, EM; Ganetsky, M; Traub, SJ; Vodonos, A, 2016) |
| "After a few days the patient developed deep vein thrombosis of the subclavian, axillary and brachial veins, which was successfully treated with nadroparin." | ( Baecker, H; Haas, NP; Märdian, S; Ranke, H, 2016) |
| "The incidence of deep vein thrombosis, bleeding events and multiple organ dysfunction syndrome (MODS) and mortality of two groups after anticoagulation therapy were analyzed." | ( Li, B; Lin, C; Sun, H; Wang, K; Zhao, X, 2015) |
| "Essentials A lowered risk of recurrent venous thrombosis (VT) with statin treatment is controversial." | ( Blondon, M; Floyd, JS; Harrington, LB; Heckbert, SR; Larson, EB; McKnight, B; Psaty, BM; Rosendaal, FR; Sitlani, CM; Smith, NL; Wiggins, KL, 2016) |
| "Sixty-two PE patients with or without deep venous thrombosis (DVT) was randomized to rivaroxaban mono-therapy or standard-therapy with enoxaparin followed by vitamin K antagonist (VKA)." | ( Chen, R; Duan, L; Guo, Y; Hong, C; Liu, C; Su, X; Yan, H; Yang, X; Zhang, N; Zhong, N; Zhou, Y, 2016) |
| "In patients with acute lower extremity deep venous thrombosis and chronic inferior vena cava occlusion the indication of the endovenous pharmacomechanical lysis therapy is questionable." | ( Berencsi, A; Csobay-Novák, C; Szeberin, Z; Tóth, GB, 2016) |
| "Patient was a known case of Deep vein thrombosis of left leg since 5 years on warfarin therapy." | ( Pai, P; Rathod, N, 2016) |
| "Methods A cohort of acute venous thrombosis patients from four anticoagulation clinics who used an LMWH and a vitamin K antagonist were followed until they ceased LMWH treatment or until major bleeding." | ( Biedermann, JS; Cannegieter, SC; Kruip, MJHA; Lijfering, WM; Reitsma, PH; van der Meer, FJM; van Rein, N; Vermaas, HW; Wiersma, N, 2017) |
| "Standard treatment of deep vein thrombosis (DVT) is based on antithrombotic therapy, initially with parenteral administration of unfractionated heparin or low molecular weight heparins (LMWH) for five to seven days, then subsequent long-term therapy with oral vitamin K antagonists (e." | ( Brandao, GM; Junqueira, DR; Rollo, HA; Sobreira, ML, 2017) |
| "In addition, a mouse venous thrombosis model was constructed and treated with miR-126-Exo to clarify the therapeutic effect of miR-126-Exo by histological analysis." | ( Liu, X; Lu, D; Ma, T; Meng, Q; Shen, Z; Sun, J; Yang, J; Yang, Z; Zhang, J; Zhang, Z, 2018) |
| "However cerebral venous thrombosis (CVT) is conventionally treated with heparin followed by oral vitamin K antagonists." | ( Akhtar, S; Kumar, P; Muthukalathi, K; Muthukumar, K; Shankar Iyer, R; Tcr, R, 2018) |
| "To evaluate the risk of deep vein thrombosis (DVT) in men treated with testosterone replacement therapy (TRT) or Clomiphene Citrate (CC) and assess other etiologies for DVT as contributing factors." | ( Ellis, AM; Kavoussi, KM; Kavoussi, M; Kavoussi, PK; Kavoussi, SK; Machen, GL; Wenzel, JL, 2019) |
| "Here, we report a case of recurrent venous thrombosis after discontinuation of rivaroxaban therapy and avoiding sedentary lifestyle in a patient with APS." | ( Abe, T; Nishiyama, S; Sata, M; Yagi, S, 2019) |
| "She had been treated with dabigatran for deep vein thrombosis." | ( Hagihara, K; Ikeda, M; Iwanari, S; Nishikawa, S; Saita, H; Shimada, H; Shimoda, S; Takeoka, H; Tanaka, M; Taniguchi, K, 2019) |
| "However, at the same time, lower limb venous thrombosis occurred, which was treated by continuous edoxaban." | ( Ando, M; Chihara, H; Hatano, T; Higashi, E; Kamata, T; Kondo, D; Nagata, I; Ogura, T; Sakai, S; Sakamoto, H; Suzuki, K; Yamagami, K, 2019) |
| "Effects of RSV treatment in vivo venous thrombosis rat model were evaluated." | ( Li, Y; Lu, Z; Wang, S; Wang, W; Yuan, X; Zhan, Y; Zhu, X, 2019) |
| "When parietal venous thrombosis (VT) were detected at the femoral vein puncture site, all patients were randomly assigned to two treatment groups." | ( Balakhonova, TV; Golitsyn, SP; Kropacheva, ES; Loginova, AI; Maykov, EB, 2019) |
| "The incidence of pulmonary embolism, deep venous thrombosis, major bleeding (MB), clinically relevant non-MB, acute respiratory distress syndrome, and in-hospital mortality was compared between patients on fondaparinux versus enoxaparin therapy." | ( Agrusta, F; Amitrano, M; Bellizzi, A; Cardillo, G; Cavalli, A; Di Micco, P; Fontanella, A; Iannuzzo, M; Lodigiani, C; Mangiacapra, S; Russo, V; Sacco, C; Viggiano, GV, 2020) |
| "The hemorrhagic form of cerebral venous thrombosis can be a diagnostic challenge and is treated by anticoagulation therapy, despite the existence of an intracerebral hemorrhage." | ( Bains, SS; Cardoso, ER; Farkas, J; Robison, B, 2021) |
| "Sixty patients with venous thrombosis in gestation period were treated as the research group, including every 30 people in the middle and late pregnancy groups, and the control group randomly selected 33 healthy pregnant women during the same period." | ( Hu, FR; Pan, QY; Tao, HP; Wang, C; Zhao, X, 2021) |
| "Here, we are reporting a case of deep vein thrombosis in a male patient in his early forties with paranoid schizophrenia, which presented on the fourth day of starting risperidone therapy." | ( George, M; Konnakkaparambil Ramakrishnan, K, 2021) |
| "Acute cerebral venous thrombosis patients were allocated to dabigatran 150 mg twice daily, or dose-adjusted warfarin, for 24 weeks, after 5-15 days' treatment with unfractionated or low-molecular-weight heparin." | ( Aguiar de Sousa, D; Bendszus, M; Caria, J; Coutinho, JM; Dentali, F; Diener, HC; Ferro, JM; Huisman, H; Jansen, O; Kobayashi, A; Miede, C; Neto, LL, 2022) |
| "The mainstay of cerebral venous thrombosis (CVT) treatment according to current guidelines is parenteral anticoagulation with unfractionated heparin or low-molecular-weight heparin followed by long-term oral anticoagulation with vitamin K antagonists." | ( Andone, S; Bajko, Z; Balasa, R; Filep, RC; Maier, S; Motataianu, A; Stoian, A, 2022) |
| "Group 1: patients with deep vein thrombosis, treated with fondaparinux plus nattokinase." | ( Cione, E; De Sarro, G; Di Mizio, G; Gallelli, G; Gallelli, L; Muraca, L; Palleria, C; Rubino, P; Salerno, M; Siniscalchi, A, 2021) |
| "Patients with venous thrombosis caused by PROS1 mutations could receive rivaroxaban as the first choice of anticoagulation therapy." | ( Huang, C; Zhang, W; Zhou, W, 2021) |
| "For acute proximal deep vein thrombosis, catheter-directed thrombolytic therapy is an accepted method for vessel recanalization." | ( Ahmed, O; Bader, KB; Bhargava, A; Hendley, SA; Holland, CK; Paul, JD; Wool, GD, 2022) |
| "History of deep vein thrombosis (DVT), location of SVT above the knee, and palpable induration were the only independent factors associated with prolonged treatment duration." | ( Chatzis, D; Georgiadis, G; Giannoukas, AD; Ioannou, C; Kakkos, SK; Karathanos, C; Latzios, P; Vasdekis, S, 2023) |
| "History of deep vein thrombosis (DVT), location of SVT above the knee, and palpable induration were the only independent factors associated with prolonged treatment duration." | ( Chatzis, D; Georgiadis, G; Giannoukas, AD; Ioannou, C; Kakkos, SK; Karathanos, C; Latzios, P; Vasdekis, S, 2023) |
| "Cerebral venous thrombosis (CVT) is a rare disease, and data regarding direct oral anticoagulant therapy are insufficient." | ( Frol, S; Oblak, JP; Šabovič, M, 2023) |